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Basal cell carcinoma (BCC) is a distinctive manifestation in nevoid basal cell carcinoma syndrome (NBCCS)
patients. Both inherited and acquired mutations of patched 1 (PTCH1), a tumor-suppressor gene controlling the
activity of Smoothened (SMO), are the primary cause of the constitutive activation of the Hedgehog (HH)
pathway, leading to the emergence of BCCs in NBCCS. LDE225, a distinct, selective antagonist of SMO, showed
potent inhibition of basaloid tumor nest formation and mediated regression of preformed basaloid tumors in
organ cultures of skin derived from Ptch1 heterozygous knockout mice. In a double-blind, randomized, vehicle-
controlled, intraindividual study, a total of 8 NBCCS patients presenting 27 BCCs were treated twice daily with
0.75% LDE225 cream or vehicle for 4 weeks. Application of 0.75% LDE225 cream was well tolerated and showed
no skin irritation. Of 13 LDE225-treated BCCs, 3 showed a complete, 9 a partial, and only 1 no clinical response.
Except for one partial response, the vehicle produced no clinical response in any of the 14 treated BCCs.
Treatment with 0.75% LDE225 cream in NBCCS patients was very well tolerated and caused BCC regression, thus
potentially offering an attractive therapeutic alternative to currently available therapies for this indication.
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INTRODUCTION
Nevoid basal cell carcinoma syndrome (NBCCS), also known as
Gorlin–Goltz syndrome, Gorlin syndrome, or basal cell nevus
syndrome, is a rare autosomal dominant disorder of high
penetrance but variable phenotype expression (Wicking et al.,
1997; Boutet et al., 2003). NBCCS has a minimum prevalence of
1:57,000 and is characterized bymultiple developmental defects
and cancer susceptibility, particularly to basal cell carcinomas
(BCCs) and several other malignant or benign tumors including
medulloblastoma as well as ovarian and cardiac fibroma (Shafei-
Benaissa et al., 1998; Lo Muzio, 2008). The most frequent
developmental abnormalities include dyskeratotic palmar and
plantar pits, odontogenic keratocysts of the jaw, ectopic
calcifications, spine and rib malformations, macrocephaly, and
generalized overgrowth (Kimonis et al., 1997).
NBCCS is usually caused by mutations in the patched
1 (PTCH1) gene. This gene has been mapped to the long arm
of chromosome 9 (q22.3) and encodes the transmembrane
protein PTCH1, the primary receptor for ligands of the
Hedgehog (HH) signaling pathway (Farndon et al., 1992;
Epstein, 2008). HH signaling regulates a variety of processes
during embryonic development and adult tissue homeostasis,
and its uncontrolled activation is known to be involved in
cancer formation (Jiang and Hui, 2008). Under physiological
conditions this pathway is actively repressed by PTCH1,
which inhibits Smoothened (SMO)—a seven-transmembrane
protein and the key activator of downstream signals. Binding
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of HH ligands to PTCH1 blocks its repression toward SMO,
thereby activating the HH signaling cascade. Consequently,
Gli transcription factors get stabilized and translocate to the
nucleus to induce gene transcription and thus control
proliferation, survival, and differentiation of HH-responsive
cells (Rohatgi and Scott, 2007; Ruiz i Altaba et al., 2007).
Emergence of BCCs in NBCCS patients in general is because of
somatic inactivation of the residual normal PTCH1 allele,
resulting in constitutive activation of SMO and consequent
uncontrolled proliferation and blockage of cellular differentia-
tion (Laimer et al., 2008). Thus, inhibition of the HH pathway
seems to be beneficial for patients suffering from this disease.
Successful treatment of locally advanced or metastatic BCCs
in humans has been proven recently after oral administration of
a specific SMO inhibitor, referred to as GDC0449, which
showed an overall response rate of 55% (Von Hoff et al., 2009).
Additionally, oral administration of GDC0449 quite impress-
ively mediated tumor regression in a patient with metastatic
medulloblastoma and significantly reduced the BCC burden in
a patient with NBCCS (Rudin et al., 2009; Goldberg et al.,
2010). We have developed LDE225, a distinct and selective
antagonist of human and murine SMO protein with single-digit
nanomolar potency in SMO binding and cellular assays
(Pan et al., 2010b), for the topical application in BCC. In this
study, we will provide evidence that this SMO inhibitor, even
when applied topically, can successfully interfere with the
HH-dependent signaling pathway in mice and humans.
RESULTS
LDE225 induces regression of murine basaloid tumor nests
Skin punches derived from Ptch1þ /LacZ heterozygous mice
were cultured in the presence of the small-molecule SMO
agonist HH Ag-1.3 (Frank-Kamenetsky et al., 2002). Because
Ptch1 is a target gene of HH signaling, the Ptch1-LacZ transgene
allows for monitoring of the pathway activation by assaying
b-D-galactosidase expression. LDE225 reduced X-gal staining of
skin explants more profoundly than cyclopamine when added
to SMO-agonist-induced cultures (Figure 1a). It has previously
been shown that basaloid tumor nests form when whole-skin
biopsies are cultured in the presence of recombinant Sonic HH
protein or a small-molecule SMO agonist (Williams et al.,
2003). LDE225 efficiently blocked basaloid tumor nest forma-
tion in skin biopsies cultured in the presence of HH Ag-1.3 with
the half-maximal inhibitory concentration (IC50) of p150nM,
whereas cyclopamine showed only weak antagonistic activity
with an IC50 ofB10mM (data not shown). In a regression assay,
basaloid tumor nests were allowed to form by stimulation with
HH Ag-1.3 for 7 days. Subsequently, LDE225 or the reference
SMO inhibitor cyclopamine was added and cultures maintained
for another 8 days in the presence of HH Ag-1.3 agonist.
Preformed basaloid tumor nests were induced to regress by the
presence of LDE225 (but not cyclopamine) with an IC50 of
p150nM (Figure 1b and c).
LDE225 inhibits HH gene expression and prevents hair growth
in mice
Activation of the HH signaling pathway plays an important
role in hair follicle morphogenesis during the early anagen
phase of the hair growth cycle (Oro and Higgins, 2003).
Therefore, hair growth inhibition could serve as a pharma-
codynamic read-out for SMO antagonists. Photographs taken
on days 15 and 22 (e.g., 1 day and 8 days after cessation of
treatment) have shown complete inhibition of anagen
progression and hair growth in all LDE225-treated animals
in contrast to vehicle controls (Figure 2). In the LDE225-
treated group, skin pigmentation as first sign of anagen
commenced on day 22, and hair growth progressed normally
thereafter. Topical application of LD225 as 1% solution
inhibited expression of Gli1, Gli2, and Sox9 transcripts
almost completely, and reduced sFRP1 (secreted frizzled-
related protein 1) mRNA levels by 80%. Treatment with 0.3%
LDE225 inhibited Gli1, Gli2, and Sox9 expression by B80,
50, and 40%, respectively, whereas sFRP1 was not affected
(Supplementary Figure S1 online).
Skin penetration/permeation studies ex vivo and in vivo
Ex vivo, a 0.3% LDE225 solution in propylene-glycol
penetrated well into the human (27±8 mg g–1) and pig
(11±3 mg g–1) skin, whereas the permeation rate through
human and pig skin was as low as 6 ng cm–2 h–1. In vivo,
topical application of the 0.75% LDE225 cream on the
dorsolateral trunk of pigs resulted in dermal concentrations of
1–1.5 mg g–1 at time points between 1 and 8 hours. Upon one
application of LDE225 to 10% body surface of pigs, dermal
concentrations of 1 mg g–1 and blood levels p0.15 ngml–1
were observed after 24 hours (data not shown).
Clinical and histopathological results after topical application of
0.75% LDE225 cream in NBCCS patients
A total of 8 patients (male: 4, 50%) with NBCCS were
enrolled into the study. Mean (range) age of all patients was
49.5 years (27–66), weight was 91.3 kg (69.4–110.7), and
height was 180.9 cm (164–196). Figure 3 represents the flow
of patients through the study. A total of 27 BCCs were treated
twice daily with 0.75% LDE225 cream or vehicle for 4
weeks. Every patient received the vehicle and the active
compound. In all, 14 lesions were treated with vehicle,
which included 7 nodular and 7 superficial BCCs, and the
active compound was applied to 13 lesions, comprising 8
nodular and 5 superficial BCCs.
LDE225 was well tolerated and did not lead to skin
irritation. Plasma LDE225 concentrations after 4 weeks were
below detection level (0.06 ngml–1) in 4/8 patients (highest
plasma level detected was 0.11 ngml–1). Mean LDE225 skin
concentrations were 737 ng g–1 (BCC) and 605ng g–1 (unin-
volved skin). No clinically significant abnormalities in
physical examination, vital signs, electrocardiographs, bio-
chemistry, hematology, or urinalysis results were recorded
during the study. Out of 13 (both nodular and superficial)
BCCs treated with 0.75% LDE225 cream, 12 showed a
clinical response (complete clinical response: 3; partial
response: 9). Except in 1 out of 14 lesions, the vehicle
produced no clinical response (Figure 4a). At the patient
level, all 8 patients showed at least partial response for
lesions treated with active compound, compared with 1 out
of 8 for lesions treated with vehicle, a difference of 87.5%.
1736 Journal of Investigative Dermatology (2011), Volume 131
H Skvara et al.
Topical Treatment of BCC in NBCCS
The probability that the matched difference between active
compound and vehicle is at least 50% was calculated to be
0.972. The clinical response parameters were defined as
follows: complete response—there is no longer any visible
evidence of a lesion consistent with BCC at this site; partial
response—although a BCC still remains at this site, it has
demonstrated a visible decrease in size compared with
baseline; no response—the BCC has not demonstrated any
visible decrease in size compared with baseline. The clinical
evaluation was performed by an investigator who was
blinded to treatment groups. Macroscopic and dermatoscopic
images of one representative tumor at baseline (before
treatment) and after 4 weeks of treatment with 0.75%
LDE225 cream are shown in Figure 4b–e. Figure 4f and g
show the three-dimensional (3D) image of the tumor at
baseline (before treatment) and after 4 weeks of treatment
with 0.75% LDE225 cream. Volumetric measurements of the
BCCs on day 29 revealed a mean tumor volume reduction of
56% in the LDE225-treated lesions (Figure 4h), and was
significantly different from the reduction in vehicle-treated
tumors (P¼ 0.011). The mean surface area reduction on day
29 was 39%, which was significantly different from that seen
with vehicle (P¼0.001; Figure 4i).
In each patient, one vehicle-treated (n¼ 8) and one
LDE225-treated BCCs (n¼ 8) were biopsied for histopatho-
logical analysis. Routine hematoxylin and eosin staining of
day 29 skin biopsies of vehicle- and LDE225-treated tumors
revealed that in all biopsied lesions tumor nests were still
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Figure 1. Regression of hedgehog (HH) Ag-1.3 preinduced basaloids in embryonic skin punches by LDE225 but not by cyclopamine. (a) Blue color due
to X-gal staining indicates b-D-galactosidase induction from the patched 1 (Ptch1) promoter; scale bar¼ 1mm. (b) Basaloid lesions represented as dark,
roundish structures of variable sizes (all such lesions are marked with black arrows in the HH Ag-1.3 (1 mM) group) were induced by incubation of
skin explants from embryonic Ptch1þ /LacZmice with HH Ag-1.3 (1 mM) for 7 days, and skin explants were maintained for another 8 days in the presence of HH
Ag-1.3 and the indicated concentrations of LDE225 or cyclopamine; scale bar¼ 0.25mm. (c) The number of lesions were counted (four slides per
condition) and plotted against the concentration of LDE225 (light gray bars) or cyclopamine (gray bars) versus positive (hatched bar) or negative
(black bar) controls.
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present. However, the number of proliferating Ki-67þ tumor
cells was significantly lower in LDE225-treated BCCs
compared with the vehicle-treated lesions. Markers for
apoptosis (TUNEL, B-cell lymphoma 2 (Bcl-2), and cleaved
caspase-3) or senescence (b-galactosidase) demonstrated no
difference between vehicle- and LDE225-treated groups.
Images for Ki-67 and data for Ki-67, TUNEL, and Bcl-2 are
presented in Figure 5 (panels ; data for cleaved caspase-3 and
b-galactosidase not shown). Gli1 (GLI family zinc-finger 1)
staining revealed various degrees of reduction of nuclear
reactivity in all the LDE225-treated BCCs compared with the
vehicle-treated group (data not shown). An example illustrat-
ing a reduction in the number and intensity of Gli1-positive
cells is shown in Supplementary Figure S2 online.
Downregulation of hedgehog target genes
Taqman quantitative real-time reverse transcriptase-PCR was
used to measure the expression levels of Gli1, Gli2, PTCH1,
and PTCH2 genes in BCC biopsies from patients treated with
0.75% LDE225 cream and vehicle. The expression levels of
Gli1, Gli2, and PTCH2 in biopsies from LDE225-treated
BCCs were downregulated 2- to 16-fold in 6/8 patients and
correlated with clinical response end points in all but one
patient (Supplementary Figure S3 online).
PTCH mutation analysis
Germline PTCH1 mutations were identified using material
from the peripheral blood from six out of eight NBCCS
patients (Supplementary Table S1 online). Two were missense
mutations (found together in two patients—patients 5 and 7—
mother and son), one was a nonsense mutation, one was
a deletion of eight amino acids, and two were frameshift
mutations leading to the truncation of the protein. One of the
frameshift mutations was accompanied by the P1315L
change, previously reported in NBCCS patients (Pastorino
et al., 2005), and was present in two other patients from this
study. All these variations were also observed in the vehicle-
and LDE225-treated tumors (germline mutations). Addition-
ally, one of the patients with germline mutations showed an
additional nonsense somatic mutation in exon 8 of PTCH1 in
the vehicle-treated biopsy, whereas one of the patients with
no germline mutation also showed a somatic nonsense
Figure 2. Efficacy of topical LDE225 to inhibit entry into anagen and hair
growth. Mice were treated once daily with a 1% solution of LDE225 applied
topically to depilated back skin. (a) On day 15, all vehicle-treated controls
have entered anagen phase with visible hair re-growth, (b) whereas almost
all LDE225-treated animals visibly remained in telogen phase. (c) Photos were
also taken 8 days following treatment cessation, i.e., on day 22, when a
complete hair coat was observed for all animals treated with vehicle,
(d) whereas LDE225-treated mice just showed signs of anagen initiation
with normal hair growth progression from day 22 onward. Shown are 4
representative animals of groups of 15.
Assessed for eligibility (n = 25)
Randomized (n = 8)
LDE225
Allocated to intervention (n = 8)
Received allocated intervention (n = 8)
Did not receive allocated intervention (n = 0)
Allocated to intervention (n = 8)
Received allocated intervention (n = 8)
Did not receive allocated intervention (n = 0)
Lost to follow-up (n = 0)
Analyzed (n = 8)
Analysis
Follow-up
Excluded from analysis (n = 0)
Analyzed (n = 8)
Excluded from analysis (n = 0)
Discontinued intervention (n = 0)
Lost to follow-up (n = 0)
Discontinued intervention (n = 0)
Vehicle
Allocation
Excluded (n = 17)
Did not meet inclusion criteria (n = 15)
Declined to participate (n = 2)
Other reasons (n = 0)
Enrollment
Figure 3. The CONSORT flowchart. In total, eight patients with multiple basal cell carcinomas (BCCs) were randomized. In every patient, selected BCCs were
randomly allocated to treatment with LDE225 or vehicle.
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mutation in the vehicle-treated tumor. Sequencing of the
PTCH2 gene in DNA from peripheral blood revealed two
previously reported missense variations (rs11573586 and
rs11573590) in two of the six patients with PTCH1 mutations.
No PTCH2 mutation was observed in patients tested negative
for PTCH1 germline mutations.
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Figure 4. Tumor response in nevoid basal cell carcinoma syndrome (NBCCS) patients after a 4-week treatment with 0.75% LDE225 cream. (a) The
results of the clinical evaluation are displayed as no response (light gray), partial response (gray), and complete response (dark gray). Macroscopic and
dermatoscopic images of a nodular ulcerated basal cell carcinoma (b, d) before (baseline) and (c, e) after treatment. Three-dimensional (3D) surface
reconstruction of the same lesion (f) before and (g) after treatment, showing a 79% volume reduction compared with baseline. Mean percentage (%)
change from baseline in (h) tumor volume (P¼ 0.011) and (i) tumor surface area (P¼ 0.001) for basal cell carcinomas (BCCs) treated with 0.75%
LDE225 cream (black) and vehicle (light gray) was measured on days (d) 8, 15, 22, and 29 (within-patient two-sided t-test referring to day 29 only).
Scale bar¼ 5mm for all micrographs.
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DISCUSSION
LDE225 is a selective antagonist of SMO that inhibits
HH-dependent signaling, with IC50s in the low nanomolar
range based on cellular assays (Pan et al., 2010b). In this
study, LDE225 efficiently mediated regression of basaloid
tumor nests induced by a specific agonist in organ cultures of
skin explants taken from embryonic Ptchþ /LacZ hetero-
zygous knockout mice with IC50 p150nM. Topical applica-
tion of LDE225 solutions to C57/BL6 mice was found to
prevent hair growth and to inhibit HH target gene expression.
Pharmacokinetic studies revealed that LDE225 penetrates
well into porcine and human skin but permeates through skin
only to a very low extent. These preclinical data suggested
that LDE225 has a high potential to interfere with the HH
pathway in BCCs after topical treatment, which encouraged
us to conduct a short-term trial in patients with NBCCS.
In the recent past, a handful of reports were published on
HH inhibitors systemically applied to humans afflicted with a
cancerous disease (Rudin et al., 2009; Von Hoff et al., 2009;
Goldberg et al., 2010; Yang et al., 2010). Overall, these
compounds showed a favorable, yet limited, response in
terms of clearance. To our knowledge, it has never been
demonstrated that a topical inhibitor of the HH pathway can
also be beneficial, in this case for patients with NBCCS. This
syndrome is hallmarked by a high penetrance of inactivating
mutations of the PTCH1 gene (Wicking and McGlinn, 2001),
leading to the development of multiple BCCs and, therefore,
served perfectly for a therapeutic trial with a topical SMO
inhibitor. In a previous trial, another SMO inhibitor termed
Cur61414 failed to show efficacy when applied in a topical
formulation to BCCs, possibly because of inadequate
penetration into the skin (Tang et al., 2007). In our proof-
of-concept study, 12 out of 13 BCCs, both nodular and
superficial, responded clinically after a 4-week twice-daily
treatment period with topical LDE225. The average volume
reduction of the LDE225-treated BCCs was 56%. A detailed
inspection of the individual data revealed that some tumors
(4 out of 13) responded rapidly in terms of volume shrinkage
by466% or surface area reduction by450% in the first 2 to
3 weeks and reached a plateau thereafter. The rest of the
responding tumors showed a slow but continuous reduction
of tumor size over the entire 4-week treatment period.
The number of Ki-67þ cells in the tumor was significantly
reduced, when measured directly after treatment on day
29 when compared with vehicle, whereas the number of
apoptotic cells revealed no difference in TUNEL and cleaved
caspase-3 staining at this time point. Using a K5-tTA/TRE-
Gli2 transgenic BCC mouse model, certain investigators
(Hutchin et al., 2005) demonstrated that after transgene
inactivation of Gli2, a key transcription factor of the HH
pathway, previously developed BCCs showed a volume
reduction of over 90% after 3 weeks. In this experiment,
distinct tumor cell apoptosis, measured by TUNEL staining,
peaked after 3 days and returned to baseline levels on day 21.
In contrast, tumor volume and Ki-67þ cells showed an
almost linear decrease until day 21. This could explain the
fact that our immunohistological results (only available from
day 29 after treatment initiation) still revealed reduced
proliferation, but did not show an increased apoptosis any
longer. Although three BCCs were considered as complete
clinical responders, none of the lesions showed evidence of
histological clearance after 4 weeks of treatment. Currently, it
remains unsolved whether topical or even systemic HH
inhibition has the potential to cause complete tumor
regression, or whether HH inhibition induces demise of only
a portion of the tumor cells, keeping cancer stem cells in a
dormant state as long as the activation of downstream
transcription factors is suppressed. In fact, a recent study
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Figure 5. Evaluation of an antiproliferative and/or proapoptotic effect of
0.75% LDE225 cream. Immunohistological analyses show representative
slides stained for proliferating cells (Ki-67þ ) after a 4-week twice-daily
treatment with (a) 0.75% LDE225 cream compared with (b) vehicle-treated
basal cell carcinomas (BCCs). (c) Box plots illustrate numbers of Ki-67þ
cells detected in epidermis, BCC tumor nests, and dermis for vehicle (n¼8,
white) and 0.75% LDE225 cream (n¼8, dark gray). The only significant
differences were observed for Ki67 in the BCC tumors. (d) B-cell lymphoma 2
(BCL-2) and (e) TUNEL staining did not reveal any significant
differences between LDE225 or vehicle groups in any compartment.
Scale bar¼ 100mm (a and b left panels); 25 mm (a and b right panels).
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suggested the latter by showing that even prolonged
inhibition of HH signaling is not sufficient to cause complete
tumor clearance, indicating the persistence of a quiescent
cell population in regressed BCC (Hutchin et al., 2005).
Future trials with different dosing and prolonged treatment
are required to answer these questions.
In line with the clinical response, we demonstrated that
the expression of Gli1, Gli2, PTCH1, and PTCH2 genes
showed a 42-fold reduction in six out of eight NBCCS
patients. In addition, Gli1 nuclear staining was reduced in all
seven BCC skin samples that were tested. These findings
confirm the efficacy of LDE225 in inhibiting the SMO
pathway. For the future, the expression of Gli1, which can
easily be demonstrated by immunohistology, might be
of relevance to select sporadic BCCs for treatment with
LDE225 cream.
The PTCH mutation analysis confirmed previous reports
from the literature regarding the different PTCH1 mutations
that can be identified in NBCCS patients (Pan et al., 2010a).
In two patients, there were also changes within exons coding
for the PTCH2 gene. Although it is well documented that loss-
of-function mutations within PTCH1 are the cause for
deregulated SMO activity, the relevance of PTCH2 for the
suppression of SMO is not fully understood. Certain
investigators (Rahnama et al., 2004) concluded that PTCH1
and PTCH2 have distinct roles and do not function similarly
in terms of SMO suppression and HH pathway activation.
This is in line with the observation that Ptch2-deficient
animals were born alive, showed no obvious defects,
and were not cancer prone, in contrast to Ptch1 deficiency
(Lee et al., 2006). However, in animals with heterozygous
deficiency of both Ptch1 and Ptch2, a higher incidence of
tumors and a broader spectrum of tumor types were observed
when compared with Ptch1 heterozygous knockout mice
(Lee et al., 2006). Therefore, it could be assumed that PTCH2
modulates tumorigenesis associated with loss-of-function
mutations of PTCH1.
Although surgical excision is the standard treatment of
BCCs, with recurrence rates between 1 and 3%, there exists
no evidence-based recommendation of how to treat BCCs in
NBCCS patients. These individuals require a dual approach,
focusing on long-term preservation of healthy skin on the one
hand and reversing the growth of invasive tumors on the
other hand. Nonsurgical interventions include cryotherapy,
photodynamic therapy, ablative laser therapy, and topical
imiquimod 5% cream (van der Geer et al., 2009). One of the
great advantages of the nonsurgical therapies is the preserva-
tion of the skin and the achievement of good cosmetic results.
However, some of these treatment modalities have high
recurrence rates (8–22%) and side effects such as erosions,
ulcerations, pain, and also scarring, which have to be
considered (Morton et al., 2008). The systemic approach of
the SMO inhibitor GDC0449 (Genentech, San Francisco, CA)
in a patient with NBCCS suffering from multiple BCCs
resulted in the clinical disappearance of nearly all BCCs, but
was also escorted by almost complete alopecia (Goldberg
et al., 2010). In contrast, topically applied LDE225 showed
an excellent safety profile with no local or systemic side
effects, while being able to induce regression in all BCCs
except one. Further exploration will demonstrate how effective
0.75% LDE225 cream can be in terms of a complete
histological clearance when applied long term, and if so,
whether persistent treatment is required to prevent the
recurrence of BCCs at treated sites. Taken together, the topical
route of administration of 0.75% LDE225 cream appears to be
an attractive alternative to surgical intervention, oral SMO
antagonists, and to other topical drugs available for BCC
treatment, which frequently cause local or systemic side effects.
MATERIALS AND METHODS
Basaloid tumor formation and regression assay in vitro
Ptchþ /LacZ heterozygous knockout mice in which the bacterial
LacZ gene is placed under the control of the promoter of the
replaced Ptch1 allele were purchased from Jackson Laboratories (Bar
Harbor, ME). Mouse embryos were collected and killed at late
gestation (embryonic day 17.5), and the skins were excised. Ptchþ /
mouse skin punch animal protocol was approved by the institutional
animal care and use committee of the Genomics Institute of
the Novartis Research Foundation. The punches were placed
in a collagen-coated Transwell (Corning Costar, Sigma-Aldrich,
St Louis, MO) with the epidermal side facing up and were incubated
at the air–liquid interface in DMEM/F12 (3:1) culture medium with
5% fetal bovine serum further supplemented with EGF (20 ngml–1;
R&D Systems, Minneapolis, MN), insulin (5mgml–1; Sigma,
Sigma-Aldrich, St Louis, MO), and hydrocortisone (0.536 mgml–1;
Sigma, Sigma-Aldrich). The presence of 1 mM of the SMO agonist HH
Ag-1.3 (Frank-Kamenetsky et al., 2002) induced basaloid lesions
within 7 days. SMO antagonists LDE225 or cyclopamine were added
at different concentrations to address their activity to inhibit basaloid
formation. In the regression assay, basaloid tumor lesions were
induced first by HH Ag-1.3, and LDE225 (1.5 mM, 750 nM, and
150nM) or cyclopamine (10, 5, and 1 mM) was added subsequently to
cultures maintained in the presence of 1mM HH Ag-1.3 for another 8
days. Pathway activation was assessed by assaying b-D-galactosi-
dase activity using 5-bromo-4-chloro-3-indolyl b-D-galactoside (X-
gal) staining of skin punches (1mgml–1 of X-gal in phosphate-
buffered saline) for 4 hours. Samples were then rinsed with
phosphate-buffered saline and fixed with 4% paraformaldehyde
and processed for histological analysis. Basaloid lesions were
evaluated by microscopy of fixed hematoxylin and eosin-stained
tissue sections and counted according to the hair follicle develop-
ment staging system as described previously (Chuong, 1998; Paus
et al., 1999). Basaloids morphologically similar to developing hair
follicles of stages 1–4 were counted in each field (average field size:
1.5mm in length and 0.25mm in width) using four fields per culture
condition. Mean basaloid counts±SEM were calculated and
plotted against the compound concentration using EXCEL (Microsoft
Corporation, Redmond, WA).
Inhibition of hair growth and HH target genes in C57/BL6 mice
by topically applied LDE225
Female C57/BL6 mice (aged 6 to 7 weeks) were depilated with a
melted beeswax/resin mixture (depilation induces hair growth in
telogen skin) when at telogen phase (pink skin color). Studies
described in this report were performed according to a notification
(y 9, O¨sterreichisches Tierversuchsgesetz) approved by the local
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governmental authority (Landesregierung Wien, Magistratsabteilung
58, Vienna, Austria). Starting 24 hours after depilation, skin areas
were treated with LDE225 dissolved in an experimental vehicle
comprising propylene-glycol and ethanol (7þ 3 volumes) once daily
for 14 consecutive days using 12 mice per test article or vehicle.
Treated skin areas were examined daily for pigment formation
(indicating start of hair re-growth) and appearance of hair.
Photographs were taken on days 15 and 22. Mice were followed
up until recovery from treatment, visible as hair re-growth. In
another experiment, LDE225 was applied as a 1 or 0.3% solution for
7 consecutive days, and skin biopsies were taken 4 hours after last
drug application for quantitative gene expression analysis by reverse
transcriptase-PCR. Biopsies were homogenized with a bead-based
homogenizer for 30 seconds with 5.5m s–1 at room temperature.
Total RNA was extracted by the Trizol method (Invitrogen, Carlsbad,
CA), and RNA concentrations and purity were determined spectro-
photometrically against a known RNA standard. RNA samples were
transcribed into complementary DNA using the high-capacity
complementary DNA ‘‘Archive Kit’’ followed by specific amplifica-
tion of 20 ng triplicate samples using the Assay-on-Demand reagents
for specific amplification and detection of mouse transcripts of the
reference gene glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; assay on demand Mm4352339E) and the specific HH
target genes Gli1, Gli2, Sox-9, and sFRP-1 (assays on demand
Mm01160468_g1, Mm01293117_m1, Mm00448840_m1, and
Mm00489161_m1, respectively, all purchased from Applied Bio-
systems, ABI, Foster City, CA). Reverse transcriptase-PCR reactions
were run on an ABI 7500 Fast Real-time PCR system machine.
Threshold cycle (Ct) values obtained for GAPDH were subtracted
from the Ct obtained for each of the target genes. Resulting DCt
values were then converted to linear positive values using the
formula 2(DCt) and multiplied by 1,000 to show relative expression
levels in the graphs.
Skin penetration/permeation studies
For ex vivo studies, saturated solutions of LDE225 in propylene-
glycol were applied epicutaneously to human cadaver skin or pig
skin mounted in static Franz-type diffusion cells. Permeation (flux)
through the skin was measured by sampling 100 ml of receptor fluid
five times up to 48 hours as described previously (Schmook et al.,
1993). Skin penetration was determined, at the end of a 48-hour
exposure time, by drug concentration measurements in the skin (after
removal of the stratum corneum). For in vivo studies, a 0.75%
experimental formulation was topically applied to 4 cm2 skin of
domestic pigs to determine dermal concentrations at selected time
points and to 10% body surface area to evaluate systemic exposure
at selected time points up to 24 hours after application by plasma
level determinations. Samples were analyzed for LDE225 in the sub
ngml–1 range by reversed-phase HPLC with mass spectrometry
detection in the MS/MS mode, using an 1100 Series LC System
(Agilent, Santa Clara, CA) coupled to a LTQ mass spectrometer
(Thermo Finnigan, San Jose, CA) as described previously (Billich
et al., 2004).
Study in NBCCS patients
Study CLDE225B2203 (EudraCT number: 2008 005506-40) was a
4-week, double-blind, randomized, vehicle-controlled study to
evaluate the safety, local tolerability, and pharmacokinetics of
twice-daily topical administration of 0.75% LDE225 cream and to
explore the pharmacodynamics in skin BCCs in NBCCS patients. The
study was conducted in Vienna (Department of Dermatology,
Division of Immunology, Allergy and Infectious Diseases, Medical
University of Vienna, Austria) after approval of the local ethics
committee of the Medical University of Vienna and the Austrian
health authority (Bundesministerium fu¨r Gesundheit, Vienna,
Austria). The study was conducted according to the principles
embodied in the Declaration of Helsinki Principles, and all patients
provided written informed consent before participating in the study.
Patients aged between 18 and 75 years with multiple BCCs, fulfilling
the diagnostic criteria for NBCCS (Kimonis et al., 1997), were
enrolled. The subjects needed to present BCCs on two different body
areas (scalp, arm, anterior or posterior trunk, and legs). Each of the
two areas selected needed to have either one BCC 410mm in
diameter or two BCCs45mm in diameter. The investigator enrolled
patients into the study and assigned a lesion number to each BCC to
be treated. Each patient was assigned a randomization number by a
central randomization office. The randomization number was linked
to a randomization scheme generated by a validated system
indicating which study treatment was to be applied to each lesion
number for each patient. The BCC(s) in the respective area was
(were) treated for 4 weeks twice daily with 0.75% LDE225 cream or
vehicle. BCCs treated with vehicle and BCCs treated with 0.75%
LDE225 cream were strictly located in different body areas. During
the treatment phase, the patients were monitored as outpatients on a
weekly basis. Blood pressure, pulse rate, and hematology/blood
chemistry laboratory parameters were examined on day –1 and
throughout the study period, including the follow-up at days 36 and
56. At the end of treatment on day 29, one skin biopsy was taken
from an LDE225-treated BCC and one skin biopsy was taken from a
vehicle-treated tumor in every patient (4-mm punch biopsy). Each
specimen was divided into four parts for further analyses (paraffin
sections, cryopreserved sections, and DNA and RNA isolation). Two
additional 4-mm punch biopsies were taken from an LDE225-treated
tumor and from perilesional LDE225-treated skin for pharmaco-
kinetic assessments from every patient.
Imaging and volumetric measurements
Digital photography including dermatoscopic, macroscopic, and 3D
images of the BCCs were performed on days 1, 8, 15, 22, and 29,
and during follow-up on days 36 and 56. The volume of the
respective lesion was measured with a special device, the ‘‘3D
LIFEVIZ Micro system’’ (QuantifiCare, Sophia Antipolis, France).
Thereby, a lens splitter is used to produce two images of the surface,
captured at the same time, with viewing angle differences close to
human vision. A stereovision algorithm is applied to reconstruct and
quantitatively analyze the skin surface in 3D.
Histopathological biomarkers
Paraffin sections from skin biopsies of LDE225- or vehicle-treated
BCCs were used for immunohistochemical analysis. To determine
the antiproliferative and/or proapoptotic effects of LDE225, we
performed Ki-67 (clone Ki-67, IgG1, DakoCytomation, Glostrup,
Denmark), Bcl-2 (clone 124, IgG1, DakoCytomation) immunohisto-
chemical staining, and TUNEL labeling (In Situ Cell Death Detection
Kit, POD; Roche Molecular Biochemicals, Basel, Switzerland)
according to the manufacturer’s instructions. Cryopreserved sections
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from vehicle- and LDE225-treated tumors were subjected to staining
for the apoptosis marker cleaved caspase-3 (cleaved Caspase-3
(Asp175) (5A1E) rabbit monoclonal antibody) and the senescence
marker b-galactosidase (both from Cell Signaling, Danvers, MA),
according to the manufacturer’s instructions. Routine hematoxylin
and eosin staining was performed on all formalin-fixed biopsy
specimens (n¼ 16) and were evaluated by a histopathologist who
was blinded to treatment groups. Immunohistochemical staining for
Gli-1 was performed using the Ventana Discovery XT (Ventana
Discovery Systems, Tucson, AZ) on skin biopsies of LDE225- and
vehicle-treated BCCs taken from seven NBCCS patients after 4 weeks
of twice-daily treatment.
Molecular biomarkers
Total RNA was extracted from BCC biopsies using the RNeasy
mini-kit from Qiagen according to the manufacturer’s
instructions (Qiagen, Hilden, Germany) and was reverse transcribed
to complementary DNA using random hexamers and the
High-Capacity complementary DNA archive kit from Applied
Biosystems.
Real-time PCR was performed using the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems). Primers were
obtained from Applied Biosystems (Supplementary Table S2 online).
The expression results for the three control genes, UBC, DNAJB12,
and C19ORF56, were used to control for intersample variability.
Data are presented graphically as fold change. Fold change is
calculated using the formula 2DDCT, where CT is the threshold cycle
(the fractional cycle number at which the amount of amplified
target reaches a fixed threshold) and DCT is the difference in
threshold cycles for the target gene and the average of the control
gene Cts. DDCT is the difference in DCT for the vehicle- and
LDE225-treated biopsies.
PTCH1 and PTCH2 sequencing analysis
Sequencing of the complete coding regions (exons and exon
boundaries) of PTCH1 (NM_000264.3) and PTCH2 (NM_0037
38.8) was performed by direct sequencing. PCR was performed
using unique primers carrying a universal M13 sequence tag
(Supplementary Table S3a and S3b online). All amplifications except
for exons 1 and 2 of each gene was performed with AmpliTaq Gold
Master Mix (Applied Biosystems) on a GeneAmp 9700 PCR System
(Applied Biosystems) according to the manufacturer’s instructions.
All sequence variations were noted and corresponding coding
changes characterized.
Statistical analysis
A total of eight patients were enrolled to ensure that six patients
completed the study. Six patients would provide at least 80%
probability that a 50% level of proof would be achieved that the
matched difference between active compound and vehicle for at
least partial response rates is at least 50%, if the true vehicle partial
response rate was p10% and the true active partial response rate
was 75%.
Patients may have been treated for one or two lesions with each
of LDE225 and the vehicle cream. For the assessment of clinical
response, where two lesions were treated with a particular treatment
for a patient, the overall patient/treatment response was determined.
If both lesions had the same level of response (no, partial, complete)
then this was the overall response for that treatment. Where the two
lesions had different responses, the overall patient/treatment
response was determined as complete response if both lesions had
complete response and partial response otherwise. The probability
that the matched difference between the at least partial response
rates (at the patient level) for active compound and vehicle is at least
50% was calculated as a posterior probability by sampling from the
joint Dirichlet distribution of the four possible outcomes (response
for both treatments, response for active compound only, response for
vehicle only, and no response for both treatments). For the analysis
of tumor volume and size derived from 3D digital photography, the
values were summed for each patient and treatment to give the total
volume and surface area for LDE225- and vehicle-treated BCCs for
each patient. The percentage change from baseline was then calculated
and compared on day 29 between LDE225 and vehicle using a within-
patient two-sided t-test. No adjustment was made for multiple testing.
Statistical analysis was performed using SAS version 9.2, SAS Institute,
Cary, NC.
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